Primary mediastinal large B-cell lymphoma

M Martelli, A Ferreri, Alice Di Rocco, M Ansuinelli, PWM Johnson

Research output: Contribution to journalArticle

Abstract

Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct clinical and biological disease from other types of DLBCL. It is more frequent in young female and constitutes 6%-10% of all DLBCL. PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis. Molecular analysis shows it to be a distinct entity from other DLBCL. Rituximab CHOP/MACOP-B-like regimens followed by mediastinal radiotherapy (RT) were associated with a 5-years PFS of 75%–85%. More intensive regimens, as DA-EPOCH-R without mediastinal RT, have shown very promising results, but this therapeutic advance needs to be confirmed in further prospective trials. The role of consolidative mediastinal RT should be still better assess in prospective comparative studies. PET-CT scan is a powerful tool to define the real quality of response and it is hoped that future prospective trials may allow its role in the de-escalation of mediastinal RT. © 2017 Elsevier B.V.
Original languageEnglish
Pages (from-to)318-327
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume113
Issue number8
DOIs
Publication statusPublished - 2017

Fingerprint

B-Cell Lymphoma
Radiotherapy
Sclerosis
B-Lymphocytes
Prospective Studies
Therapeutics

Cite this

Primary mediastinal large B-cell lymphoma. / Martelli, M; Ferreri, A; Di Rocco, Alice; Ansuinelli, M; Johnson, PWM.

In: Critical Reviews in Oncology/Hematology, Vol. 113, No. 8, 2017, p. 318-327.

Research output: Contribution to journalArticle

Martelli, M, Ferreri, A, Di Rocco, A, Ansuinelli, M & Johnson, PWM 2017, 'Primary mediastinal large B-cell lymphoma', Critical Reviews in Oncology/Hematology, vol. 113, no. 8, pp. 318-327. https://doi.org/10.1016/j.critrevonc.2017.01.009
Martelli, M ; Ferreri, A ; Di Rocco, Alice ; Ansuinelli, M ; Johnson, PWM. / Primary mediastinal large B-cell lymphoma. In: Critical Reviews in Oncology/Hematology. 2017 ; Vol. 113, No. 8. pp. 318-327.
@article{486b661636d447a480e3debb43f953a2,
title = "Primary mediastinal large B-cell lymphoma",
abstract = "Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct clinical and biological disease from other types of DLBCL. It is more frequent in young female and constitutes 6{\%}-10{\%} of all DLBCL. PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis. Molecular analysis shows it to be a distinct entity from other DLBCL. Rituximab CHOP/MACOP-B-like regimens followed by mediastinal radiotherapy (RT) were associated with a 5-years PFS of 75{\%}–85{\%}. More intensive regimens, as DA-EPOCH-R without mediastinal RT, have shown very promising results, but this therapeutic advance needs to be confirmed in further prospective trials. The role of consolidative mediastinal RT should be still better assess in prospective comparative studies. PET-CT scan is a powerful tool to define the real quality of response and it is hoped that future prospective trials may allow its role in the de-escalation of mediastinal RT. {\circledC} 2017 Elsevier B.V.",
author = "M Martelli and A Ferreri and {Di Rocco}, Alice and M Ansuinelli and PWM Johnson",
year = "2017",
doi = "10.1016/j.critrevonc.2017.01.009",
language = "English",
volume = "113",
pages = "318--327",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "8",

}

TY - JOUR

T1 - Primary mediastinal large B-cell lymphoma

AU - Martelli, M

AU - Ferreri, A

AU - Di Rocco, Alice

AU - Ansuinelli, M

AU - Johnson, PWM

PY - 2017

Y1 - 2017

N2 - Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct clinical and biological disease from other types of DLBCL. It is more frequent in young female and constitutes 6%-10% of all DLBCL. PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis. Molecular analysis shows it to be a distinct entity from other DLBCL. Rituximab CHOP/MACOP-B-like regimens followed by mediastinal radiotherapy (RT) were associated with a 5-years PFS of 75%–85%. More intensive regimens, as DA-EPOCH-R without mediastinal RT, have shown very promising results, but this therapeutic advance needs to be confirmed in further prospective trials. The role of consolidative mediastinal RT should be still better assess in prospective comparative studies. PET-CT scan is a powerful tool to define the real quality of response and it is hoped that future prospective trials may allow its role in the de-escalation of mediastinal RT. © 2017 Elsevier B.V.

AB - Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct clinical and biological disease from other types of DLBCL. It is more frequent in young female and constitutes 6%-10% of all DLBCL. PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis. Molecular analysis shows it to be a distinct entity from other DLBCL. Rituximab CHOP/MACOP-B-like regimens followed by mediastinal radiotherapy (RT) were associated with a 5-years PFS of 75%–85%. More intensive regimens, as DA-EPOCH-R without mediastinal RT, have shown very promising results, but this therapeutic advance needs to be confirmed in further prospective trials. The role of consolidative mediastinal RT should be still better assess in prospective comparative studies. PET-CT scan is a powerful tool to define the real quality of response and it is hoped that future prospective trials may allow its role in the de-escalation of mediastinal RT. © 2017 Elsevier B.V.

U2 - 10.1016/j.critrevonc.2017.01.009

DO - 10.1016/j.critrevonc.2017.01.009

M3 - Article

VL - 113

SP - 318

EP - 327

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 8

ER -